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What is the key question? 
Does WFDC12 possess innate defence properties similar to other WFDC proteins in the lung 
such as SLPI and elafin? 
 
What is the bottom line? 
We have functionally characterised a member of the WFDC family of proteins, WFDC12, and 
have shown it to possess antiprotease and anti-inflammatory activity and to be present at 
elevated levels in the respiratory tract of patients with acute respiratory distress syndrome 
(ARDS). 
 
Why read on? 
Given its properties we speculate that WFDC12 may play a role in protecting lung tissue 
during inflammation and infection. 
 
 
 
Author Contribution 
AMAG SW AS DMS DTM and NC performed the experiments; UH COK DP DFM PMN JSE and 
FTL provided biological samples; SH carried out analysis; AMAG SW and CCT designed 
experiments and drafted manuscript. All the authors reviewed the manuscript and approved 
its submission.  
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ABSTRACT 
 
Secretory leukocyte protease inhibitor (SLPI) and elafin are members of the whey acidic 
protein (WAP), or WAP four-disulphide-core (WFDC), family of proteins and have multiple 
contributions to innate defence including inhibition of neutrophil serine proteases and 
inhibition of the inflammatory response to lipopolysaccharide (LPS). This study aimed to 
explore potential activities of WFDC12, a previously uncharacterised WFDC protein 
expressed in the lung. Recombinant expression and purification of WFDC12 were optimised 
in Escherichia coli. Recombinant WFDC12 inhibited cathepsin G, but not elastase or 
proteinase-3 activity. Monocytic cells pre-treated with rWFDC12 before LPS stimulation 
produced significantly lower levels of the pro-inflammatory cytokines IL-8 and MCP-1 
compared to cells stimulated with LPS alone. Recombinant WFDC12 became conjugated to 
fibronectin in a transglutaminase-mediated reaction and retained antiprotease activity. In 
vivo WFDC12 expression was confirmed by immunostaining of human lung tissue sections. 
WFDC12 levels in human bronchoalveolar lavage fluid from healthy and lung-injured 
patients were quantitatively compared, showing WFDC12 to be elevated in both patients 
with acute respiratory distress syndrome and healthy subjects treated with LPS, relative to 
healthy controls. Together these results suggest a role for this lesser known WFDC protein in 
the regulation of lung inflammation. 
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INTRODUCTION 
 
Members of the whey acidic protein (WAP)5, or WAP four-disulphide-core (WFDC), family of 
human proteins are defined by the presence of one or multiple WAP domains – a 40-50 
amino acid sequence containing eight conserved cysteine residues that fold to form four 
disulphide bonds[1]. The most studied members of this group of proteins are secretory 
leukocyte protease inhibitor (SLPI) and elafin, both of which contribute significantly to the 
innate immune response via their antiprotease, antimicrobial and anti-inflammatory 
activities. As a result, they have each been involved in clinical trials as potential therapeutic 
agents to aid the control of inflammation[2,3]. 
 
The small molecular weight proteins SLPI and elafin are found constitutively expressed in 
lung epithelia and other mucosal surfaces, demonstrating upregulation in response to a 
range of pro-inflammatory stimuli such as bacterial lipopolysaccharide (LPS), neutrophil 
elastase, IL-1β and TNF-α[4]. They are also produced by inflammatory cells such as 
neutrophils and macrophages[4]. 
 
SLPI and elafin each function as inhibitors of elastase, with elafin also inhibiting proteinase-
3[4]. SLPI shows no inhibition of proteinase-3 but instead is active against cathepsin G, 
trypsin and chymotrypsin[4]. Both proteins are bactericidal against Gram negative and Gram 
positive species of bacteria[5,6], and display notable antifungal[4,6] and antiviral 
effects[7,8]. SLPI and elafin also play important immunomodulatory roles through their 
ability to reduce the host response to LPS. This is understood to occur by both extracellular 
and intracellular mechanisms[9–12]. 
 
The role of most other WFDC proteins remains largely unknown. Our focus here is on 
WFDC12 (also known as WAP2).  Without the predicted signal peptide, the mature 88 amino 
acid protein has an estimated molecular weight of 9.7 kDa and an isoelectric point of 
5.77[13]. It has a N-terminal WAP domain and a C-terminal region showing no significant 
homology with any currently recognised motifs[13]. The WFDC12 gene is found highly 
expressed in lung, skin, prostate and oesophageal tissue[13]. Whilst the murine homolog 
5 
 
protein SWAM2 has been shown to have antibacterial properties[14], there has been no 
data on the function of human WFDC12 reported in the literature.  
 
The primary aim of this research was to investigate if WFDC12 harboured host defence 
properties akin to SLPI and elafin. Recombinant expression and purification of WFDC12 in E. 
coli were first optimised, followed by evaluation of the protein’s antiprotease, antibacterial 
and immunomodulatory action. Recombinant WFDC12 (rWFDC12) was found to inhibit 
activity of the serine protease cathepsin G. No antibacterial ability was observed, but 
rWFDC12 inhibited LPS-induced cytokine production in THP-1 monocytic cells. Similar to SLPI 
and elafin, rWFDC12 was found to be capable of binding the extracellular matrix protein, 
fibronectin, and retained its antiprotease activity. Finally we show WFDC12 expression in 
human lung tissue via immunohistochemistry, and quantify WFDC12 levels in supernatants 
from LPS-treated THP-1 cells and bronchoalveolar lavage fluid (BALF) from a range of patient 
cohorts. 
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METHODS 
 
Recombinant WFDC12 expression and purification 
The mature WFDC12 cDNA sequence was cloned by Gene Art (Life Technologies, Paisley, 
UK) into a pQE30 vector (Qiagen, West Sussex, UK) with a six histidine coding sequence 5’ to 
the cloning region. His-tagged rWFDC12 protein was expressed and purified as detailed in 
the Online Supplement.  
 
Protease activity assays  
Cathepsin G activity was measured using the fluorogenic substrate Suc-Ala-Ala-Pro-Phe-
AMC (100 μM; PeptaNova, Sandhausen, Germany) as outlined in the Online Supplement. 
Neutrophil elastase and proteinase-3 activity were measured using MeOSuc-Ala-Ala-Pro-Val-
AMC (50 μM; Enzo Life Sciences, Exeter, UK).  
 
Radial diffusion assays 
The type strain bacteria Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 
25923 and E. coli ATCC 25922 were routinely maintained at 37°C on Colombia Blood Agar 
plates with 5% sheep blood (Southern Group Laboratories, Northamptonshire, UK). Double 
layer radial diffusion assays were carried out as described previously[15]. Bacteria were 
washed and resuspended in 10 mM sodium phosphate (pH 7.4) buffer before incorporation 
into agarose underlay gels based on the same buffer. Full details are given in the Online 
Supplement. 
 
Cell culture experiments and cytokine ELISAs 
Experiments using THP-1 cells and measurement of cytokine release were carried out as 
outlined in the Online Supplement.  
 
Cross-linking of rWFDC12 to fibronectin and evaluation of antiprotease activity of 
fibronectin-bound rWFDC12 
Transglutamination reactions were based on previously described methods[16,17], with 
minor modifications using rWFDC12 and fibronectin (see Online Supplement). 
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Immunostaining of human tissue from an ex vivo lung perfusion (EVLP) model 
Lungs harvested from potential donors which were found to be unsuitable for 
transplantation were obtained from IIAM (International Institute for Advancement of 
Medicine). Ethical approval for the use of these samples was obtained from the Queen’s 
University Belfast School of Medicine, Dentistry and Biomedical Science Research Ethics 
Committee (Reference Number 12.17). The lungs were perfused ex vivo based on previously 
described methods[18]. Briefly, the lungs were initially rewarmed over a period of 1 hr by 
perfusion of the pulmonary artery using DMEM (high glucose, 4.5 g/L) containing 5% 
albumin, which was contained in a reservoir surrounded by a heated water bath (38°C). The 
lungs were gently inflated with continuous positive airway pressure (10 cmH2O, 95% O2, 5% 
CO2). Fresh whole human blood (anticoagulated using acid citrate dextrose) was added to 
the perfusate once physiological temperatures were reached, and LPS (6 mg) was then 
introduced intrabronchially into a pre-selected lobe via a PE catheter (BD, 240 tubing). 
Experimentation ceased 4 hr after LPS instillation, upon which tissue samples for histology 
were taken from both non-LPS (control) and LPS-perfused lobes. Immunostaining methods 
for WFDC12 and selected cell markers (epithelial cells: pan cytokeratin, macrophages: CD68, 
neutrophils: neutrophil elastase) are detailed in the Online Supplement. 
 
Human BALF collection and measurement of WFDC12 
WFDC12 levels were evaluated in BALF samples obtained from a number of different clinical 
trials: Samples from patients within 48 hours of ARDS onset (n = 27) were taken from the 
HARP study[19]. LPS-treated healthy subjects (50 μg LPS, BALF at 6 hr post LPS-inhalation, n 
= 10) and healthy controls (n = 5) were taken from a separate study[20]. Additional healthy 
controls (n = 6) were taken from the ongoing ARENA study. Ethical approval for the use of 
samples from the HARP (ISRCTN70127774), LPS (ISRCTN21056528) and ARENA 
(NCT01659307) studies was granted by the local institution and the local research ethics 
committee (REC numbers 06/NIR02/77, 06/NIR02/91 and 12/NI/0082 respectively). A 
description of the bronchoalveolar lavage procedure, sample processing and quantification 
of WFDC12 levels by ELISA is outlined in the Online Supplement. 
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Statistical analysis 
All data were analysed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) 
and are reported as mean ± SEM. Results are representative of at least n = 3 unless 
otherwise indicated. Means were compared by unpaired t-test or one-way analysis of 
variance (ANOVA) as appropriate with Tukey’s post-hoc test. Statistical significance is 
indicated as: * P < 0.05, ** P < 0.01, *** P < 0.001.  
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RESULTS 
 
Purification of rWFDC12 –The rWFDC12 used for the experiments in this study was purified 
under denaturing conditions as outlined in the methods section with a typical yield of 
approximately 8 mg per litre of culture. SDS-PAGE assessment showed the final product 
contained some multimers but was mostly rWFDC12 in monomeric form (Fig. 1A). The level 
of purity was reproducibly high. Identity of the purified protein was confirmed by 1D nLC-
MS-MS (reverse phase chromatography). 
 
Antiprotease activity of rWFDC12 – Since SLPI and elafin are known to be potent inhibitors 
of neutrophil serine proteases in the lung, we tested rWFDC12 for similar activity. Cathepsin 
G protease activity (213 nM) was inhibited by rWFDC12 in a dose-dependent manner (Fig. 
1B), with almost complete inhibition by the highest rWFDC12 amount tested (9.1 μM). No 
significant inhibition of elastase or proteinase-3 activity by rWFDC12 was observed (data not 
shown). 
 
Antibacterial assays – The WFDC proteins SLPI and elafin are reported to demonstrate 
notable antibacterial effects and so we investigated the ability of rWFDC12 to inhibit the 
growth of the type strain bacteria P. aeruginosa ATCC 27853, S. aureus ATCC 25923 and E. 
coli ATCC 25922. Concentrations of up to 72.7 μM of protein were tested via radial diffusion 
assays but did not exhibit antibacterial effects (Fig. 2). The antimicrobial peptide cecropin A 
was used as a positive control.  
 
Effect of rWFDC12 on LPS challenge in monocytic cells – The previously documented ability 
of SLPI and elafin to inhibit LPS-induced production of cytokines in monocytic cells led us to 
investigate if WFDC12 had similar properties. THP-1 monocytic cells were pre-treated with 
rWFDC12 for 1 hr before stimulation with LPS for 16 hr. Measurement of secreted cytokines 
via ELISA showed that cells pre-treated with rWFDC12 had significantly lower levels of IL-8 
(Fig. 3A) and MCP-1 production (Fig. 3B), but not IP-10 (data not shown).  
 
Ability of rWFDC12 to bind fibronectin – SLPI and elafin can each become cross-linked to 
extracellular matrix proteins, including fibronectin, in a transglutaminase catalysed reaction. 
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To examine if WFDC12 behaved in a similar manner, rWFDC12 was incubated with 
fibronectin and guinea pig liver transglutaminase for 2 hrs at 37°C. As observed by Western 
blot sample analysis, high molecular weight complexes (>250 kDa) appeared when rWFDC12 
and fibronectin were incubated together in the presence of transglutaminase, but not when 
transglutaminase was absent (Fig. 4A). Accordingly, fibronectin was found depleted as 
visualised in a Colloidal blue stained gel (Fig. 4B). The heat-inactivated transglutaminase 
control reaction served to further certify that formation of the complexes was the result of 
specific enzymatic activity. 
 
Antiprotease activity of fibronectin bound rWFDC12 – In order to determine if fibronectin-
conjugated rWFDC12 was still able to inhibit cathepsin G activity, rWFDC12 was added to 
fibronectin-coated wells of a 96-well plate, with/without transglutaminase. Unbound 
protein was washed away before addition of cathepsin G and fluorogenic substrate and the 
rate of substrate hydrolysis was monitored every 60 seconds for 1 hr. Wells containing 
transglutaminase and rWFDC12 showed approximately 26% less cathepsin G activity 
compared to wells with cathepsin G and transglutaminase in the absence of WFDC12 (Fig. 
4C), indicating that immobilised rWFDC12 still functioned as an inhibitor. The level of 
inhibition was conceivably less than that observed with 5 μg of soluble rWFDC12 (Fig. 1B), 
since the cross-linking reaction is not wholly efficient. Wells containing rWFDC12 in the 
absence of transglutaminase showed no inhibition of cathepsin G activity (Fig. 4C), 
confirming specificity of the transglutaminase catalysed reaction.  
 
Immunostaining of WFDC12 in human tissue sections – Human lungs rejected for 
transplant were perfused with LPS as outlined in the Methods section. Tissue samples from 
non-LPS (control) and LPS-perfused lobes were used for immunohistochemistry. Sections 
incubated with WFDC12 antibody showed positive staining (not detectable with isotype 
control) which correlated with epithelial, macrophage and neutrophil staining patterns (Fig. 
5). WFDC12 expression was more apparent in tissue from LPS-perfused lung lobes due to 
increased infiltration of immune cells. 
 
Quantification of WFDC12 in THP-1 supernatants and human BALF samples – The presence 
of a signal peptide suggested that WFDC12 could be secreted from cells; therefore we used 
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an indirect ELISA for measurement of WFDC12 in cell-free supernatants. THP-1 cells 
stimulated with LPS for 4 hr showed significantly increased WFDC12 secretion (Fig. 6A). 
Furthermore, we quantified WFDC12 levels in BALF from healthy patients and patients with 
lung injury. BALF from ARDS patients showed significantly increased WFDC12 relative to 
healthy controls (Fig. 6B). In addition, healthy volunteers administered LPS also showed 
significantly higher WFDC12 levels when compared to healthy controls (Fig. 6B).  
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DISCUSSION 
 
SLPI and elafin are well characterised members of a family of proteins which each carry 
cysteine-rich motifs known as WFDC domains. Both SLPI and elafin have similar 
contributions to innate host defence via their inhibition of serine proteases, antimicrobial 
properties and dampening of the inflammatory response to LPS[4,21]. In order to 
investigate the role of WFDC12 in similar areas of host defence, we firstly optimised 
recombinant expression and purification of the protein, then tested it for a range of 
functions. We found antiprotease and immunomodulatory properties, but no antibacterial 
activity. Furthermore, the antiprotease action of rWFDC12 was preserved when it was 
immobilised to fibronectin.  
 
Although SLPI is composed of two WAP domains, its antiprotease activity has been mapped 
exclusively to just one of these, the C-terminal WAP domain[22]. Elafin’s antiprotease 
activity has been proven to reside in its single WAP domain[23]. Recent scrutiny of WAP 
domains from human WAP proteins challenged the previous supposition that all of these 
proteins are protease inhibitors[21]. Spacing of the eight conserved cysteine residues in the 
domain was identified as fundamental in the determination of inhibitory potential[22,23]. 
The inhibitory active sites of the SLPI and elafin domains lie between cysteines 2 and 3, 
which are separated by eight amino acids. Among the other aligned WAP domains, this 
space was sometimes just three residues, leading to the proposal that, upon folding, these 
proteins would not contain adequate space for an inhibitory active site[21]. However, the 
spacing within this area of WFDC12 is relatively large (seven residues), leading us to 
hypothesise that WFDC12 could also, like SLPI and elafin, harbour antiprotease properties. 
Indeed, our data confirms rWFDC12 as an inhibitor of the neutrophil serine protease 
cathepsin G. We speculate that the specificity of WFDC12 towards inhibition of cathepsin G, 
but not elastase or proteinase-3, is due to the presence of a phenylalanine residue in the 
putative inhibitory active site. This is a relatively large, hydrophobic amino acid which may 
not fit the smaller active sites of elastase or proteinase-3. 
 
The antimicrobial activities of SLPI and elafin are associated with their cationic nature (net 
charges of +12 and +3 respectively) which facilitates them to disrupt the anionic bacterial 
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cell membrane[6]. However, antimicrobial peptides/proteins may also be anionic and 
function via alternative mechanisms[24]. Of particular interest to us, the mouse protein 
SWAM2 (homolog of WFDC12), is known to be anionic and anti-bacterial[14]. We therefore 
looked for similar function of WFDC12 (also anionic) against selected type strain bacteria. 
No apparent antibacterial effects were observed with the concentrations of rWFDC12 
tested, (up to 72.7 μM), however we cannot rule out the possibility that WFDC12 may be 
effective against other species of bacteria. 
 
Elafin, its precursor trappin-2, and SLPI have each been shown to become cross-linked to 
various extracellular matrix proteins such as fibronectin and elastin via a transglutaminase-
mediated reaction[16,17]. They are also known to retain their antiprotease effects whilst 
immobilised[16,17], and we have demonstrated that rWFDC12 follows suit. We hereby build 
upon the previously outlined theory that trapping of protease inhibitors by extracellular 
matrix proteins serves to protect tissue from excessive degradation by neutrophil serine 
proteases released during inflammation[16,17]. The combination of increased exposure of 
extracellular matrix proteins and increased transglutaminase activity observed under 
inflammatory conditions is presumed to amplify conjugation of these inhibitors[16]. 
 
Elafin and trappin-2 each contain one or multiple Gly-Gln-Asp-Pro-Val-Lys consensus 
sequence motifs, a recognised substrate for the transglutaminase enzyme[16]. The SLPI 
molecule lacks this transglutamination consensus sequence, yet also readily conjugates with 
fibronectin and elastin in a similar reaction[17]. Mass spectrometry was used to identify the 
transglutaminase-reactive Gln and Lys residues within each of these three proteins[17]. 
WFDC12 also lacks the aforementioned motif, but contains several Gln and Lys residues 
which could be responsible for the fibronectin-conjugation we have shown here.  
 
We have also demonstrated the anti-inflammatory nature of rWFDC12 in its ability to inhibit 
LPS-induced cytokine production. Although the effect does not appear as potent as the 
classical examples, SLPI and elafin, we acknowledge the limitations of our recombinant 
protein production in E. coli. Furthermore, since LPS can activate many signalling pathways 
within cells, WFDC12 may target one pathway exclusively and not others, thereby limiting 
the degree of inhibition observed in cytokine release. With regards to the mechanism of 
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inhibition, it is possible that WFDC12 is complexing with LPS or IL-8/MCP-1 to reduce the 
signal detected. However, considering that SLPI and elafin can function via an effect on 
intracellular signalling molecules such as IB/β[9,12], we would anticipate that WFDC12 
also has intracellular effects on LPS signalling.  
 
We have shown in vitro that WFDC12 secretion is significantly increased in LPS-treated THP-
1 cells. WFDC12 was detectable in human clinical samples by both immunohistochemistry of 
lung tissue sections and analysis of BALF via ELISA. The levels of WFDC12 in ARDS BALF were 
slightly lower than, but still comparable to, that of SLPI and elafin. WFDC12 was detected at 
13.6 (± 1.2) ng/ml, equivalent to 1.24 (± 0.11) nM; we have previously reported nanomolar 
levels of SLPI (approximately 8.75 nM) and elafin (approximately 5.11 nM) in BALF from 
ARDS patients[25]. The significantly elevated levels of WFDC12 (relative to healthy controls) 
found in BALF from ARDS patients and healthy volunteers post LPS-inhalation may represent 
an upregulation and/or increased secretion of WFDC12 from epithelial and immune cells as 
part of the acute response to inflammation. Taken together, the results from this study 
suggest that WFDC12 may offer protective effects to the host via its antiprotease and anti-
inflammatory properties. 
 
An imbalance between endogenous proteases and their respective inhibitors is understood 
to be a major contributing factor to the pathology of various inflammatory lung diseases 
including ARDS and cystic fibrosis (CF)[26,27]. Antiproteases have therefore become a focal 
point for development of new treatments for diseases such as these, and are yielding 
promising results. For example, recent studies with 1-antitrypsin augmentation have 
demonstrated a reduction in protease activity, neutrophil number and pro-inflammatory 
cytokine levels[28,29]. SLPI is another attractive therapeutic candidate given its additional 
antimicrobial/anti-inflammatory properties, and delivery of aerosolised SLPI showed 
favourable results in CF trials[2]. However, deposition of the protein to poorly ventilated 
areas of the CF lung was later shown to be not wholly efficient[30]. In addition, it is now 
known that both SLPI and elafin are prone to proteolytic cleavage by the excessive levels of 
proteases associated with dysregulated inflammation[25,31], perhaps limiting their full 
therapeutic capacity. Therefore WFDC12 should ideally be examined for similar 
susceptibility before investigation as a possible therapy. 
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Further exploration of WFDC12 properties is needed to determine its potential as a 
therapeutic agent in chronic inflammatory disorders of the lung. Given that elafin inhibits 
elastase and proteinase-3 but not cathepsin G, combination with WFDC12 would result in 
the targeting of all three neutrophil serine proteases and could prove more highly effective. 
Furthermore, delivery of WFDC12 as a fibronectin-conjugate may offer advantages of 
increased bioavailability and stability in an environment laden with proteases. 
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FIGURE LEGENDS 
 
FIGURE 1. A. A typical rWFDC12 preparation. Induced E.coli M15 were harvested and lysed 
in a denaturing buffer. Cleared bacterial lysate was allowed to bind Ni-NTA agarose at 4˚C 
for 1-2 hr, then poured into a column and washed extensively. The eluted rWFDC12 was 
refolded via a step-wise dialysis protocol before analysis by Coomassie stained gel and 
Western blot (polyclonal rabbit anti-WFDC12 antibody). B. WFDC12 inhibits the activity of 
the serine protease cathepsin G. Cathepsin G (213 nM) was incubated alone or with 
rWFDC12 for 15 min before addition of a fluorogenic substrate (Suc-Ala-Ala-Pro-Phe-AMC). 
SLPI was used as a positive control. Results are expressed as percentage of control 
(untreated cathepsin G). 
 
FIGURE 2. Radial diffusion assay testing potential antimicrobial activity of WFDC12. Bacteria 
were incubated with a range of rWFDC12 concentrations. Cecropin A and water were used 
as positive and negative controls respectively. 
 
FIGURE 3. Investigation of potential anti-inflammatory activity of WFDC12. THP-1 monocytic 
cells were incubated for 16 hr with media alone (control), LPS or rWFDC12; or pre-treated 
with rWFDC12 for 1 hr before stimulation with LPS for 16 hr. A. IL-8 and B. MCP-1 secretion 
were measured by ELISA. Statistical significance is indicated as: * P < 0.05, ** P < 0.01, *** P 
< 0.001. 
 
FIGURE 4. WFDC12 binds fibronectin via a transglutaminase mediated reaction. 
Recombinant WFDC12 (5 μg) was incubated with fibronectin (20 μg) and guinea pig liver 
transglutaminase (1 mU) in 200 mM Tris HCl pH 7.5, 20 mM CaCl2 and 0.1 mM DTT for 2 hr 
at 37°C. Reactions were terminated upon addition of sample treatment buffer without 
reducing agent, boiled and subsequently analysed by SDS-PAGE. A. Samples were separated 
in both 7.5% and 15% gels, then assessed via Western blot with a polyclonal rabbit anti-
WFDC12 antibody. The 7.5% gel (upper panel) was used to view cross-linked protein (>250 
kDa) whilst unbound rWFDC12 was viewed on the 15% gel (lower panel). B. Samples were 
separated in a 7.5% gel and stained with Colloidal blue to allow visualisation of fibronectin 
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and rWFDC12-fibronectin complexes. C. WFDC12 complexed to fibronectin inhibits 
cathepsin G activity. Recombinant WFDC12 (4.5 μM) or buffer alone was incubated 
with/without guinea pig liver transglutaminase (1 mU) in fibronectin coated wells (20 
μg/well) of a 96-well plate for 2 hr at 37°C. Unbound rWFDC12 was washed away before 
addition of cathepsin G (213 nM) and subsequent incubation for 15 min at 37°C. Fluorogenic 
substrate was then added and relative fluorescence recorded every minute for 1 hr. W = 
rWFDC12; F = fibronectin; Tg = transglutaminase; Hi = heat inactivated. 
 
FIGURE 5. Expression of WFDC12 and cell specific markers in human lung tissue. Lungs 
deemed unsuitable for transplantation were perfused ex vivo, with LPS introduced to a 
selected lobe for 4 hr. Tissue samples from control and LPS-perfused lobes were formalin-
fixed and paraffin-embedded for immunohistochemistry. Tissue sections were stained with 
rabbit anti-WFDC12, mouse anti-pan cytokeratin (epithelial cell marker), mouse anti-CD68 
(macrophage marker) and mouse anti-neutrophil elastase (neutrophil marker). 
Representative images (n = 2) were taken at X 40 objective lens magnification. Brown 
stained cells indicate the localisation of positive staining. Scale bars shown represent 50 μm. 
 
FIGURE 6. Quantification of WFDC12 in THP-1 supernatants and human BALF samples. A. 
THP-1 monocytes were stimulated with LPS for 4 hr and WFDC12 secretion measured by 
ELISA. B. WFDC12 was measured by ELISA in BALF samples from the following patient 
groups: Healthy controls (n = 11), healthy subjects sampled 6 hr following LPS inhalation (n = 
10), and patients within 48 hr of ARDS onset (n = 27). Statistical significance is indicated as: * 
P < 0.05, *** P < 0.001. 
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